Azitra, INC 10-Q quarterly reports

Azitra, Inc. files its Q2 2026 10-Q, detailing continued operational losses and efforts to regain NYSE listing compliance, alongside significant financing activities.

Azitra, Inc. reported a significant increase in net loss and received a NYSE American delisting notice, raising substantial doubt about its ability to continue as a going concern.

Azitra, Inc. reported increased net losses and significant cash burn, raising substantial doubt about its ability to continue as a going concern, despite progress in clinical trials and new financing efforts.

Azitra Inc. announces its financial results for the first quarter of 2025, highlighting ongoing clinical trials for ATR-12 and ATR-04 while acknowledging substantial doubt about its ability to continue as a going concern.

Azitra Inc. announced its third quarter 2024 financial results, highlighting advancements in clinical trials for its lead product candidates and ongoing research and development efforts.

Azitra Inc., a clinical-stage biopharmaceutical company, reported its financial results for the second quarter ended June 30, 2024, highlighting ongoing clinical trial progress and strategic partnerships.

Azitra Inc. reported a net loss of $2.9 million for the first quarter of 2024, while highlighting progress in clinical trials and ongoing financial uncertainties.